Cullinan Therapeutics, Inc.
CGEMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cullinan Therapeutics, Inc. focuses on Biotechnology services and products. Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. Valued at $953.8M, CGEM is a small-cap name in its sector. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Market Cap
$953.8M
Beta
-0.09
P/E (TTM)
—
P/E (Fwd)
-6.10
EPS (TTM)
$-3.37
EPS (Fwd)
$-2.54
ROE
-48.2%
ROA
-30.6%
Cash
$351.9M
Total Debt
$2.4M
Free CF
-$102.8M
52W Change
78.8%
Annual Financials
Cash vs Debt
With $351.9M in cash and $2.4M in debt, CGEM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$102.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -48.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
CGEM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CGEM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cullinan Therapeutics, Inc. and its sector.